Squarepoint Ops LLC Sells 36,055 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Squarepoint Ops LLC cut its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 70.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,042 shares of the company’s stock after selling 36,055 shares during the quarter. Squarepoint Ops LLC’s holdings in Stoke Therapeutics were worth $203,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in Stoke Therapeutics in the second quarter worth approximately $29,000. Nisa Investment Advisors LLC grew its holdings in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Stoke Therapeutics during the second quarter valued at $123,000. State Board of Administration of Florida Retirement System purchased a new stake in Stoke Therapeutics during the first quarter valued at $141,000. Finally, BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after acquiring an additional 6,636 shares during the period.

Stoke Therapeutics Trading Up 3.9 %

Shares of NASDAQ:STOK opened at $11.84 on Friday. The stock has a 50 day moving average of $13.79 and a 200 day moving average of $13.72. The company has a market cap of $623.38 million, a PE ratio of -5.43 and a beta of 0.97. Stoke Therapeutics, Inc. has a 12-month low of $3.35 and a 12-month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The firm had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. Equities research analysts predict that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 11.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on STOK. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.